Fibrosis — excessive collagen deposition that replaces functional tissue with scar — occurs in skin (keloids, hypertrophic scars), liver, kidney, lung, and heart after injury or chronic inflammation. Normal healing produces organized collagen; fibrosis produces disordered cross-linked collagen that impairs function. Peptide research targets the inflammatory TGF-β driven fibrotic cascade while promoting normal tissue remodeling.
1. BPC-157 — Anti-Fibrotic / TGF-β Modulation
BPC-157 has demonstrated anti-fibrotic effects in multiple organ systems by modulating TGF-β signaling — the primary driver of fibroblast-to-myofibroblast transition that produces excessive scarring. It reduces collagen cross-linking enzymes (LOX), promotes organized matrix remodeling, and significantly reduces scar tissue formation in animal wound healing models.
Dosing Protocol: 250–500 mcg SubQ daily, or injected directly into/around scar tissue for local effects. Oral BPC-157 (500 mcg) for GI/liver fibrosis. Cycle: 8–12 weeks.
2. GHK-Cu — Collagen Remodeling / Scar Softening
GHK-Cu uniquely both stimulates collagen synthesis AND activates matrix metalloproteinases (MMPs) that break down disorganized scar collagen — a dual action that promotes replacement of fibrotic tissue with organized, functional collagen. Topically applied to scars, GHK-Cu has demonstrated visible scar softening and normalization.
Dosing Protocol: Topical: 0.5–2% GHK-Cu applied directly to scar tissue 2x daily. Systemic: 1–2 mg SubQ daily for internal fibrosis (liver, lung). Combine for skin scars.
3. TB-500 — Inflammation Control / Normal Matrix Deposition
TB-500 reduces the persistent inflammatory signaling (IL-1β, TNF-α, TGF-β1) that drives fibroblasts toward fibrotic rather than regenerative behavior. It promotes normal wound healing architecture rather than the chaotic collagen deposition of scarring, and reduces the stiffness and contracture associated with mature scars.
Dosing Protocol: 2 mg SubQ twice weekly for 4–6 weeks. Reduce to 2 mg weekly for maintenance. Best combined with BPC-157.
4. Thymosin Alpha-1 — Immune-Driven Fibrosis Control
In fibrosis driven by immune dysfunction (autoimmune hepatitis, pulmonary fibrosis, IBD), Thymosin Alpha-1 normalizes the Th1/Th17 imbalance perpetuating the pro-fibrotic inflammatory state. By restoring regulatory T-cell function, it removes the immunological driver of ongoing fibrosis without globally suppressing immune competence.
Dosing Protocol: 1.5 mg SubQ twice weekly for 4 weeks, then 1.5 mg weekly. Cycle: 8–12 weeks.
BPC-157 targets the TGF-β pathway most directly responsible for fibrotic transformation of healing tissue. GHK-Cu provides the unique dual action of breaking down existing scar collagen while promoting organized replacement. TB-500 normalizes the inflammatory environment to prevent new fibrosis while Thymosin Alpha-1 addresses immune-driven fibrotic conditions at the root.
- Seiwerth S et al. (2018). BPC-157 anti-fibrotic mechanisms. Peptides.
- Pickart L et al. (2018). GHK-Cu MMP activation and scar remodeling. Int J Mol Sci.
- Goldstein AL et al. (2010). Thymosin beta-4 and wound healing. Peptides.
- Goldstein AL et al. (2018). Thymosin alpha-1 and fibrosis. Int Immunopharmacol.
Research Use Only. All information on this page is for educational purposes only and is not medical advice. PepSherpa does not sell peptides. Consult a licensed healthcare provider before making any health decisions. Many of the studies cited are preclinical (animal/in-vitro).